-
Clinical, Cosmetic and Investigational Dermatology
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Infliximab in the treatment of plaque type psoriasis
Review
(15572) Total Article Views
Authors: Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio Chimenti
Published Date April 2009 Volume 2009:2 Pages 27 - 37
DOI: http://dx.doi.org/10.2147/CCID.S3413
Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, Italy
Abstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.
Keywords: psoriasis, nail psoriasis, infliximab, long-term treatment
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS) is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Sebusuppressive efficacy of the antioxidant bis-ethylhexyl hydroxydimethoxy benzylmalonate in the treatment of oily and blemished skin
- Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
- Treatment of cellulite based on the hypothesis of a novel physiopathology
- Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease